Preferred Label : enfortumab vedotin;

Details


Keyword's position in hierarchy(ies) : arborescence

Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3576072/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2025
false
false
false
France
Urothelial Carcinoma
evaluation of the transparency committee
enfortumab vedotin
carcinoma
enfortumab vedotin

---
https://www.has-sante.fr/jcms/p_3477569/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2023
France
evaluation of the transparency committee
enfortumab vedotin
enfortumab vedotin
carcinoma
Urothelial Carcinoma
Enfortumab Vedotin

---
https://www.has-sante.fr/jcms/p_3395521/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2022
France
evaluation of the transparency committee
enfortumab vedotin
enfortumab vedotin

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.